SurvivorNet on MSN

Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients

Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
MedscapeOpinion

EGFR Combo Trial Shows Benefit but Misses What Clinicians Need for First-Line Decisions

Dr Mark Kris breaks down the lazertinib-amivantamab data, noting that the combo shows benefit but fails to address key ...
Oregonian

Dear Doctor: How does blood test eGFR number reflect kidney function, and what range is ‘normal’?

DEAR DR. ROACH: I am a 73-year-old female. A recent blood test returned an eGFR (estimated glomerular filtration rate) of 59. My physician’s nurse told me that the test was normal. When I asked her ...
AOL

What Is EGFR and How Does It Relate to Lung Cancer?

In the past several years, our understanding of lung cancer has become much more detailed and nuanced. "When I started [practicing medicine about 20 years ago], lung cancer was just small cell lung ...
The American Journal of Managed Care

City of Hope’s Afkhami Discusses NSCLC With EGFR Exon 20 Insertion-Positive Mutations

Michelle Afkhami, MD, of City of Hope, joins The American Journal of Managed Care® (AJMC®) for a discussion on EGFR exon 20 insertion positive mutations in non-small cell lung cancer. Michelle Afkhami ...
Cure Today

What Patients With Lung Cancer Need to Know About EGFR PACC Mutations

CURE spoke with Dr. Xiuning Le during the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. Lung cancer research has recognized the role of EGFR ...

FDA approves first subcutaneous drug for EGFR-mutated non-small cell lung cancer

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Nature

Do fourth-generation EGFR inhibitors showcase the future of kinase inhibitors?

20 years on from the approval of the first intentional kinase inhibitor, the field remains locked in a battle of trial and error. For proof, look no further than EGFR ...
CURE

Rybrevant Faspro FDA-Approved as First Sub-Q Therapy for EGFR NSCLC

The U.S. Food and Drug Administration (FDA) have granted approval to Rybrevant Faspro (amivantamab and hyaluronidase-lpuj), the first and only subcutaneous therapy for patients with epidermal growth ...